Category Archives: Physiology

Learning From a Father-Son Marathon Team – The New York Times

The new study in fact grew out an earlier scientific examination of the unexpected prowess of Tommy Hughes, an electrician from Northern Ireland, who set a single-age world record last year when he turned 59 and ran a scorching 2:30:15 marathon. That finish caught the attention of researchers at the Inserm research organization in France and other institutions who study elite athletes. They invited Mr. Hughes to their lab to delve into what had allowed him to be so swift.

Mr. Hughes owned, they found, an impressive, if front-loaded running rsum. As a young man, he had represented Northern Ireland in an Olympics marathon, but then quit running for 16 years to work and raise a family. After that hiatus, he nonchalantly signed up for the 2008 Belfast marathon and, with little training, finished sixth. From there, his speed and results only improved.

An almost preternatural aerobic capacity most likely aided him, the researchers found when they tested his physiology. At 59, his capacity remained exceptionally high for his age, despite years without running, which should have reduced his endurance more permanently than it had. His current approach to training was probably crucial, the scientists decided. Uncoached, he logged at least 100 weekly miles, running twice a day and entering local 5-kilometer and 10-kilometer races for speed work.

During this testing, Mr. Hughes mentioned that he and his 34-year-old son Eoin were planning to enter the Frankfurt marathon, aiming to break the Guinness world record for fastest parent-child marathon finish, which stood then at 5:02:12. Eoin, his father told them, had not begun running until he turned 30. Now, the two of them often trained and competed together locally. This would be Eoins first marathon.

The researchers quickly realized that the father and son represented a remarkable test case of how different trajectories and biologies affect athletic success, with one runner beginning young, stopping and returning, and the other not starting until adulthood. Plus, they were related.

See original here:
Learning From a Father-Son Marathon Team - The New York Times

Keep the immune system strong and healthy – Royal Gazette

Published Mar 18, 2020 at 8:24 am(Updated Mar 18, 2020 at 8:27 am)

Keep your immune system strong: a Us Transportation Security Administration agent hands a passport back to a traveler as she screens travelers, at a checkpoint inside an airline terminal at John F. Kennedy Airport in New York on March 14, 2020. The coronavirus pandemic thats caused many Americans to avoid airports has others booking spur-of-the moment trips at dirt-cheap ticket prices (Photograph by Kathy Willens/AP)

Dear Sir,

It is certain that the potential killer strain of the coronavirus is global, which means that our island should take this threat seriously.

While emphasis has been placed on practising good hygiene principles, keeping the immune system strong and healthy is equally important.

What is the immune system? According to the anatomy and physiology for health professionals, the immune system is a series of cells, chemicals and barriers that protect the body from invasion by pathogens such as bacteria and viruses.

How can we keep the immune system strong and healthy? Eat plenty of fruits and vegetables and whole grains.

Exercise regularly, get enough sleep, practise good hygiene, take vitamins, especially Vitamin C and, of course, drink an adequate amount of water daily.

What groups are most susceptible to the coronavirus? Persons with respiratory disorders such as chronic obstructive pulmonary disease, chronic bronchitis, asthma, persons with sickle-cell anaemia and other blood disorders.

Also included, persons with diabetes, liver or kidney disorders or patients on dialysis and cancer patients.

People whose immune systems are already compromised by illness are at a higher risk. So, while practising good hygiene, let us try and keep the immune system strong.

CYNTHIA DeSILVA

Pembroke

Read more here:
Keep the immune system strong and healthy - Royal Gazette

Around the House: In praise of more human-friendly lighting – Ottawa Citizen

Each Shaws sink bears the name of the artisan who poured, shaped, and glazed it. Supplied

If you were to shrink human evolution into 24 hours, artificial light would have existed for a mere seven seconds. Having been around for such a relatively short time, its had an out-sized effect on the way people work, play, and sleep.

British neuroscientist Dr. Karen Dawe concedes that while there have been enormous benefits from artificial light, it can be hard on humans, whose behavior has been directed for millennia by the rising and setting of the sun.

Daylight changes in colour and intensity throughout the day, says Dawe, who after 17 years as a neuroscientist at Bristol University joined the lighting team at technology juggernaut Dyson in 2017. With most domestic lighting you flick a switch and it comes on at its brightness and colour temperature and it stays like that until you switch it off. Thats completely at odds with what our visual system has adapted to.

Parabola faucets in matte black make a boldly minimalist statement.Supplied

The Dyson gig, which combines research with home product development, is a good fit for Dawe, who has long been fascinated by how lifestyle and the environment affect physiology.Her brief now includes developing lighting that improves quality of life.

It starts with an understanding of the crucial role light plays in human experience, says Dawe. We care now about our air quality, where our water comes from and whats in it. But as primarily visual creatures, we consume light massively. To date, we have not really paid attention to the quality of light and what its doing to us. But the Circadian rhythms you see in everything algae, bacteria, funguses are fundamental drivers of our existence

The material Victoria + Albert freestanding tubs are made with has high insulation properties, so water stays warmer longer.Supplied

Dawes contribution to more human-friendly light came as part of a team that created Dysons Lightcycle Morph, the second iteration of a light fixture that tracks natural daylight, intelligently transforms it for the users task, age, mood, and local daylight, and continually adjusts colour temperature and brightness.

How does it do that? The short answer is that by using data from over a million atmospheric measurements of light conditions in the earths atmosphere at different times of day, a 32-bit microcontroller continually interprets and communicates data to a very sensitive optical driver.

There are pre-set study, relax, precision, boost, wake-up, and sleep modes, and users can assign up to 20 custom settings. Recognizing, for example, that a 65-year-old needs up to four times more light than a 20-year-old, the light also corrects brightness based on the age entered into the app. Its also designed to reduce the flicker that can cause eye strain and fatigue. Dimming and colour temp can be controlled manually, and the unit has a USB-C charger for phones and tablets.

The fixture uses three warm and three cool LEDs. To solve the overheating often associated with them, a heat-pipe technology that draws heat away from LEDs using a bead of water was devised. According to Dyson, that means light quality will last unchanged last 60 years.

Theres space in the Canadian market for a strong luxury brand, says Sarah Nyugen.Supplied

The optical head rotates 360 degrees, so light can be bounced off walls, floors and ceilings, or above a favourite piece of art.

A colour-warming orange filter can reduce colour temperature low enough to simulate the glow of candlelight. Thats exactly what is most sympathetic to your body clock at night a warmer, dimmer light, says Dawe.

The Lightcycle Morph is available at Dyson Demo stores in Toronto and Vancouver and on DysonCanada.ca. Desk lights start at $850. Black/Black and White/Silver finish combinations are available.

Dawe believes thoughtfully-designed lighting can not only improve visual health, but enhance physical and mental well-being. When I was studying biology, you learned about each system separately, she says. More recently, people realize that the human body doesnt actually respect those divisions that these systems all interact, all the time.

See the article here:
Around the House: In praise of more human-friendly lighting - Ottawa Citizen

Social recession: how isolation can affect physical and mental health – The Guardian

As the Covid-19 pandemic continues, millions of people in the US are coming to terms with being increasingly cut off from society.

Beyond the inconvenience of working from home, or not being able to go to bars, restaurants or cinemas, however, experts have found that social isolation can have a profound effect on peoples physical, as well as mental health.

Long-term, isolation even increases the risk of premature death. Its being called a social recession to match any economic downturn also caused by the growing pandemic and it can have profound physical and psychological effects.

People who are more socially connected show less inflammation, conversely people who are more isolated and lonely show increased chronic inflammation. Chronic inflammation has been implicated in a variety of chronic diseases, said Julianne Holt-Lunstad, a professor of psychology and neuroscience at Brigham Young University.

We also have evidence that this is linked to cardiovascular function like blood pressure, heart rate, circulating stress hormones. Its been linked to even cellular ageing.

Bars and restaurants have been ordered closed in at least 11 states, including California, Illinois and New York, while more than 30 states have closed down schools. On Monday people in six counties in northern California were ordered to stay at home, one of the strictest measures yet in the US. France had imposed a lockdown which only allows people to make trips to supermarkets, pharmacies and their workplaces should working from home not be an option, while Germany has closed places of worship, playgrounds and non-essential shops.

As countries across the globe hunker down, Holt-Lunstads research presents a stark look at what social isolation over a period of years can do to the body. She examined data from across the globe to study the effects of people being socially isolated or lonely, or living alone.

Loneliness increases earlier death by 26%, social isolation by 29% and living alone by 32%

Each of these significantly predict risk for premature death, Holt-Lunstad said.

Loneliness increases earlier death by 26%, social isolation by 29% and living alone by 32%.

Holt-Lunstad didnt find that one cause of death was more prevalent than another. The risk of every cause of death including heart disease, cancer, stroke, renal failure increased from isolation.

A period of a few weeks in isolation should not lead to the inflammation and risk of cardiovascular trouble that Holt-Lunstad described. People could still see an impact on their health, however.

We do have evidence that these [periods of shorter isolation] can have immediate and short-term kinds of effects on our physiology. But, for instance, if your blood pressure is elevated acutely, thats going to have a different kind of an effect than if your blood pressures elevated chronically, Holt-Lunstad said.

For those with underlying pre-existing conditions, those acute elevations might precipitate some sort of acute event. But for most of the rest of us, who may not have some kind of underlying condition, we hope that this would just be acute and wouldnt have these long-term effects.

One of the reasons people can suffer in social isolation is because personal relationships can help us cope with stress, Holt-Linstad said.

For instance: the ongoing uncertainty of whats going on right now in the world, your bodys response to that may differ. Depending on the extent to which you feel like you have the resources you need to cope with that. And that in large part may be dependent on whether or not you feel like you have others in your life you can rely on. That youve got someone who has your back or you can count on, or you can get through it together.

Dhruv Khullar, a physician and researcher at Weill Cornell Medicine in New York, said short periods of isolation can cause increase anxiety or depression within days.

We have evolved to be social creatures. For all the history of humanity, people have been in family structures, people have been in groups, were evolved to kind of crave and rely on that interaction with other human beings, Khullar said.

So when we dont have that its a huge void in the way that we go about being human. This is something that has been kind of hard-wired into who we are as beings.

Khullar, who stressed the crackdown on social gatherings was necessary, said people do at least have a wealth of options to stay connected. Texting, video calling or even the phone could potentially help avert the sense of isolation or loneliness, Khullar said.

Tech isnt a perfect substitute. Physical contact, being face to face with people, theres all sorts of subtle social cues that we pick up on that we rely on, that are ingrained in us over generations and millennia, he said.

But I do think you can get part of the way there by engaging with others digitally. I think the richer the format, probably the better so a phone call is better than a text, a video conference is probably better than a phone call.

Older people, who are more at risk of Covid-19, may be less technologically savvy, and may have fewer connections to begin with. They might not be able to video conference or even send a text message. Khullar said it was important to reassure them that help is at hand.

Lets look out for the people that are most vulnerable, Khullar said.

Make sure that youre reaching out to them to make sure that theyre doing OK, that they understand that there are people still looking out for them that theyre bonded with, that theyre connected with.

Here is the original post:
Social recession: how isolation can affect physical and mental health - The Guardian

Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis -…

Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a Highly Fragile and Extremely Difficult to Treat Population with Severe Sepsis

Nes Ziona, Israel, March 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced positive final safety and efficacy data from the Companys completed Phase Ib clinical trial in patients with severe sepsis. The final analysis compared the clinical data of 10 patients admitted to the intensive care unit with sepsis who were administered off-the-shelf AllocetraTM (Allocetra-OTS) upon their admission, with 37 patients who were matched controls (matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection source) who received only the standard of care treatment at the same hospital during 2014-2019 but did not receive Allocetra-OTS. The clinical trial was conducted at Hadassah Medical Center, which is one of the largest and most prestigious hospitals in Israel (Haddasah).

The primary aim of the clinical trial was to determine the safety profile and tolerability of . In addition, effects on, mortality, organ dysfunction and number of hospitalization days in general and in the intensive care unit (ICU) were measured.

MortalityThe Acute Physiology and Chronic Health Evaluation (APACHEII) score of the Allocetra OTS-treated group was 12.3, and the corresponding probability of mortality of at least one patient in that group was predicted at 85% based on the hospitals ICU staffs clinical assessment of each patients overall condition at admission. However, none (0%) of the Allocetra-OTS-treated patients died during the 28-day study period, as compared to 27% 28-day mortality in the matched controls group.

Sepsis & Organ FailureEach of the 10 Allocetra-OTS-treated patients had between 2 to 5 dysfunctional organ systems upon admission to the ICU. All (100%) of the Allocetra-OTS-treated patients had rapid and complete recovery from their septic conditions and of any organ dysfunction that was present upon admission to the ICU. Despite the similarity of organ-failure state (SOFA) at entry between the Allocetra-OTS-treated patients and the matched controls group (average of 3.4 versus 3.47), not a single patient treated with Allocetra-OTS had any increase in organ-failure state post administration of Allocetra-OTS, while the majority of the patients in the matched controls group had an increase in organ-failure state. The average worsening in organ-failure state of patients in the matched controls group was approximately 100% compared with their ICU hospitalization state vs zero (0%) percent worsening in organ-failure state of Allocetra-OTS-treated patients post administration of Allocetra-OTS (p< <0.0001).

Duration of ICU HospitalizationThe ICU length-of-stay for all Allocetra-OTS-treated patients was significantly shorter than those patients who received only the standard of care, with an average of 4 days compared to 11.11 in the matched controls group, a 64% reduction (p<0.0001). The slowest ICU discharge of a patient treated with Allocetra-OTS was after 8 days, while approximately 50% of the matched controls group were still at the ICU after 28 days.

SafetyAllocetra-OTS was shown to be safe and tolerable, with no serious unexpected severe adverse reactions and no serious adverse events.

Prof. Dror Mevorach, Chief Medical Officer of Enlivex, commented, We were excited to observe such deep and durable responses at a well-tolerated dose in this highly fragile and extremely difficult to treat septic population, and obtaining statistically-significant differences from the matched historical controls group. We believe that Allocetra-OTS is positioned as a potentially clinically viable option for treatment of sepsis, which is a clinical condition that has poor clinical outcomes and no currently effective therapy.

Oren Hershkovitz, CEO of Enlivex, stated, Allocetra-OTS is a significant product candidate for Enlivex, and the robust results of this study are highly encouraging. We are compiling patients cytokine storm data in an effort to analyze the potential of Allocetra-OTS in other clinical indications whose pathophysiology is highly correlated with cytokine storms and exaggerated immune responses.

Study designThe aim of this study was to determine the safety and efficacy profile and tolerability of Allocetra-OTS, in subjects admitted to the emergency room with sepsis. Allocetra-OTS (140x106 cells/kg) was administered in either a single dose to 6 patients at day 1 or in two doses to 4 additional patients at days 1 and 3, to patients admitted to the emergency room with sepsis. Patients were followed for 28 days. The study subjects were also compared to historical controls hospitalized in the ICU, matched by age, gender, Sequential Organ Failure Assessment (SOFA) score, and infection source.

Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated immune response to infection. Sepsis has been identified by the World Health Organization as a global health priority and currently has no FDA-approved pharmacologic treatment. Sepsis is the third leading cause of mortality in the United States after cardiovascular and cancer diseases and affects approximately 1.7 million adults in the United States each year. Various studies have estimated that up to 50% of severe sepsis hospitalizations culminate in death.

AllocetraTMis an experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose lethal pathophysiology hyper stimulation of the immune response and cytokine storm followed by organ failure that may be similar to that of the coronavirus (COVID-19) associated with the newly recognized virus SARS-CoV-2.

ABOUT ENLIVEXEnlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing. For more information, visithttp://www.enlivex.com.

Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as expects, plans, projects, will, may, anticipates, believes, should, would, could, intends, estimates, suggests, has the potential to and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRATMprograms. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivexs business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRATMproduct line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivexs filings with the Securities and Exchange Commission, including in the Companys most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

ENLIVEX CONTACT: Shachar Shlosberger, CFO Enlivex Therapeutics, Ltd. shachar@enlivexpharm.com

Read more:
Enlivex Announces Positive Final Safety and Efficacy Data From Clinical Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis -...

How light, other sensory pollution impacts animal… – ScienceBlog.com

A new paper including research from a Utah State University scientist provides a framework for understanding how light and noise pollution affects wildlife. The framework is the product of an effort among worldwide experts in ecology and physiology and reveals the presence of sensory danger zones, or areas where sensory pollutants influences animal activity. The study is published in the journalNature Ecology and Evolution. The paper is a collaborative work with principal investigator Neil Carter, assistant professor at the School for Environment and Sustainability. From a conservation biology point of view, we dont know how to mitigate the effects of sensory pollution if we dont know what the pathway of harm is, said Carter.

Although these results have consequences for imperiled species of conservation concern, they also suggest ways by which we may use light and sound for managing urban wildlife, mitigating wildlife-vehicle collisions, or preventing agricultural damage. said David Stoner, a research assistant professor in the Quinney College of Natural Resources at USU.

In their study, the authors give an example of New York Citys annual 9/11 memorial tribute. The tribute coincides with birds annual migration from northern regions to wintering grounds in Latin America. Because birds use celestial cues during their migration, the 44 spotlights that form two pillars of light can attract up to 15,000 birds in a single night.

(The birds) will fly in circles inside the beams until morning, often dying from exhaustion and collisions with artificially lit structures, according to Carter and co-lead authors Davide Dominoni, a researcher of biodiversity, animal health and comparative medicine at the University of Glasgow; and Wouter Halfwerk, assistant professor in the Department of Ecological Science at VU Amsterdam University.

Both light pollution and traffic noise can mimic natural stimuli. For example, artificial lights cover the glow of the moon, preventing birds or insects from detecting it, or traffic noise can mask the audio spectral frequency of bird song, the researchers say.

These pollutants can also redirect an animals attention away from its task: a cougar hunting deer can be distracted by headlights or road noise.

If we understand the mechanism at play, perhaps we can devise specific interventions and solutions to adopt to minimize the effect of anthropogenic impacts, Dominoni said. For instance, light has a lot of properties. By changing some of these properties, we might very well minimize the impact light pollution has on wildlife.

Night lighting and anthropogenic sound are not localized to certain habitats and certain countries. Its a global phenomenon, he said. Clarifying these mechanisms can help develop solutions to biodiversity loss and anthropogenic impacts worldwide.

Read more from the original source:
How light, other sensory pollution impacts animal... - ScienceBlog.com

Student Coronavirus Tracking Website Tops Nearly 1.4 Million Views From 193 Countries – UVA Today

Find the latest information on the Universitys response to the coronavirus here.

TrackCorona, a COVID-19 tracking website developed by two University of Virginia students, James Yun and Soukarya Ghosh, and friends at Virginia Tech and Stanford University, is proving to be a valuable public service for anyone who wants to know more about the development of the pandemic. The website went live in early February with only a smattering of clicks by people who already knew about the site. Now, more than 300,000 people in 193 countries have visited the website about 1.4 million times.Were averaging more than 40,000 users per day for the last week, with a record 50,000 users on March 12, said Ghosh, a third-year computer science and mathematics major who helped lead development of the site. Were on trajectory for 50,000 more on the 16th.

TrackCorona provides up-to-date information about the spread of the virus, including infection and mortality rates, recovery rates and locations by country, with links to the latest news and accurate information. The student team uses data from the World Health Organization, the U.S. Center for Disease Control and other infectious disease information sources. The data is made visual with a near-real-time map that displays the growth of the pandemic.

The students have consulted with several UVA faculty members in the development of their site, seeking to optimize the quality of the data and information.

Dr. Christopher Holstege, director of UVA Student Health, is serving as a contact to the students for medical questions. Wladek Minor, a professor of molecular physiology and biology physics, has offered the students an opportunity to co-write a research paper analyzing the spread of COVID-19. David Leblang, a professor of politics and public policy, has proposed a research role for the students in a study on the cascading effects of the pandemic. And Bryan Lewis, an epidemiologist at UVAs Biocomplexity Institute, has offered advice and a summer internship.

Fellow students also have proposed ideas to Yun and Ghosh and suggested sources for reliable information about the virus and its spread.

Its not every day that you get to work on something with this large of an audience and potentially save lives, Yun, a fourth-year computer science major, said. Being part of this startup-like journey has taught me how to manage exponential user growth, seek funding and deal with the occasional cyberattack.

This summer Yun will begin work as a software engineer at Capital One, where he says he will use the skills hes picked up along the way, in his classes and through development of the website.

TrackCorona is a visually compelling website, well designed, user-friendly, full of relevant information, epidemiologist Bryan Lewis said. The team has done a nice job of creating this, especially considering their busy schedules as students. It is a form of citizen science that is valuable to the community.

TrackCorona is a nominee for the Social Good of the Year award by the Charlottesville Business Innovation Council; as well as for Innovator of the Year; and Student Entrepreneurs of the Year awards. The students are seeking funding to keep the site operating, as costs for cloud computing and other resources are running about $350 per day.

Doing this work has been very fulfilling, Ghosh said. I already had a strong urge to do work that would benefit the welfare of the public, and this experience has further engrained and confirmed that for me. I hope to continue to do similar work in my career after UVA, using the skills I have learned here to make an even bigger impact.

Read more:
Student Coronavirus Tracking Website Tops Nearly 1.4 Million Views From 193 Countries - UVA Today

Coronavirus: Why an Outright Ban of Wildlife Trade Could Be Counterproductive – The National Interest

The wildlife trade has long been closely linked to disease outbreaks. It has been implicated in the SARS epidemic of 2002, Ebola in 2013 and now in the COVID-19 coronavirus.

In response to the COVID-19 outbreak, China has tentatively banned the farming of many wildlife species. The move has been celebrated by many in the international community.

But our work in Asia over the past ten years tells a different story. Banning legitimate snake farms might prove counterproductive to disease suppression.

Though snakes were early suspects as the source of the Wuhan coronavirus, reptiles have never been linked to any of the World Health Organisations top ten infectious diseases which pose the greatest threat of epidemics.

Snakes are different

One reason is straightforward. Snakes are cold-blooded (more correctly ectothermic) and have a very different physiology to humans. Viruses co-evolve highly specialised relationships with their hosts and are often species-specific.

Occasionally, a chance mutation might allow a virus to infect another species, but the more different the new and old hosts are to each other, the less likely that is.

Compared with transmission between mammals, or even from birds to mammals, the probability of a virus crossing from a cold-blooded reptile to a warm-blooded human is remote.

In parts of Asia where H5N1-type viral outbreaks such as bird and swine flu are now endemic, hundreds of snake farmers rely on waste protein such as pork and poultry by-products as feed.

Disease outbreaks regularly wreak havoc with conventional livestock industries but never, to our knowledge, with snake farming.

In this context, reptiles represent a natural biological barrier to viral diseases.

They enable farmers to build financial resilience through diversity, dampening the many risks associated with livestock monocultures.

And the benefits dont end there.

Theyre tailor-made for sustainability

Commercial snake farming has developed rapidly in China. The first experimental farms were set up in 2007; by 2019 the industry was producing large-scale high-quality protein.

Some snakes have highly desirable agricultural traits including rapid growth, early maturation and rapid reproduction. They are comparatively simple cognitively, and do not suffer the complex behavioural stresses seen in many caged birds and mammals.

Many are semi-arboreal, spending time in trees, allowing farms to maximise available space.

They do require a high-protein diet but, since their cold-blooded metabolic demands are very low (less than 10% of similar-sized mammals), food can be more directly channelled to growth.

The energy efficiency is achieved mainly by employing solar energy (e.g., basking) to drive metabolic processes, and by powerful digestive systems capable of breaking down even bone.

It means they produce low volumes of biological waste and greenhouse gases, and require minimal fresh water.

Chinese snake farms rely on two principal sources of feed inputs: waste protein from agricultural food chains, and natural prey such as harvested rodents.

This means they both recycle agricultural waste and control economically important rodent pests.

Their cold-blooded physiology allows them to survive for considerable time without food and water far longer than similarly-sized warm blooded animals.

This allows farmers to effectively exploit seasonal abundances during times of plenty, and downscale inputs during times of famine.

Snake farming therefore provides a resilient livelihood in the face of economic volatility and the extremes of Climate Change.

It would be a shame if concern about coronavirus snuffed out an industry that is unlikely to be the problem, but could very well be a solution.

Daniel Natusch, Honorary Research Fellow, Macquarie University; Graham Alexander, Professor of Herpetology, Environmental Physiology and Physiology, Ecology and Evolution, University of the Witwatersrand; Ngo Van Tri, Conservation biologist, Institute of Tropical Biology, and Patrick Aust, Research Associate, Department of Zoology, University of Oxford

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Image: Reuters

Follow this link:
Coronavirus: Why an Outright Ban of Wildlife Trade Could Be Counterproductive - The National Interest

Nitric Oxide Industry Outlook to 2028 – Pathways, Physiology, Disease, Pharmacology, Therapeutic Applications, Drugs, Therapy Markets, Companies – P&T…

DUBLIN, March 13, 2020 /PRNewswire/ -- The "Nitric Oxide - Therapeutics, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.

Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2018 and is projected to 2023 and 2028 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.

Several companies have a product or products involving NO and free radicals. The report includes profiles of 35 companies involved in this area of which 9 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 18 collaborations in this area are tabulated.

There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 26 tables and 30 figures. It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.

The report contains information on the following:

The report describes the latest concepts of the role of nitric oxide (NO) in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.

Nitric oxide (NO) can generate free radicals as well as scavenge them. It also functions as a signaling molecule and has an important role in the pathogenesis of several diseases. A major focus is delivery of NO by various technologies. Another approach is modulation of nitric oxide synthase (NOS), which converts L-arginine to NO. NOS can be stimulated as well as inhibited by pharmacological and gene therapy approaches.

Important therapeutic areas for NO-based therapies are inflammatory disorders, cardiovascular diseases, erectile dysfunction, inflammation, pain and neuroprotection. The first therapeutic use of NO was by inhaltion for acute respiratory distress syndrome (ARDS). NO-donors, NO-mimics and NOS modulators are described and compared along with developmental status. NO-related mechanisms of action in existing drugs are identified.

Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.

For more information about this report visit https://www.researchandmarkets.com/r/m3rdb1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/nitric-oxide-industry-outlook-to-2028---pathways-physiology-disease-pharmacology-therapeutic-applications-drugs-therapy-markets-companies-301022870.html

SOURCE Research and Markets

Visit link:
Nitric Oxide Industry Outlook to 2028 - Pathways, Physiology, Disease, Pharmacology, Therapeutic Applications, Drugs, Therapy Markets, Companies - P&T...

Coronavirus: sequencing the DNA of patients screened for coronavirus might save lives – The Conversation UK

Scientists should start sequencing the genomes of coronavirus patients. We should look for DNA differences between patients who are severely affected and those with mild symptoms. This could allow us to predict who else would be vulnerable and advise them to take precautions. We may be able to use this knowledge against the coronavirus epidemic before a vaccine is widely available.

In particular, it would be valuable to know if key DNA variations are shared by those rare people who are young and appeared to be healthy but developed severe symptoms from the coronavirus. We might then be able to predict which doctors and nurses are most at risk and remove them from the front line.

Of course, we dont yet know if accurate predictions will be possible. We dont even know if someones chances of severe symptoms from the coronavirus are affected by their genes. We could, however, answer these questions relatively cheaply and rapidly by using commonplace DNA sequencing technology.

Read more: Will warmer weather stop the spread of coronavirus?

We would need to sequence the whole genomes of coronavirus victims who need intensive care and compare them with the genomes of people who have only mild symptoms. With only a few thousand genomes from each category, we could quickly find out if there is mileage in this approach.

It may be that just one or two genes are involved. Perhaps broken genes involved in the immune system or lung cell surfaces. If so, we could quickly discover them using a method called genome-wide association study. If just a couple of broken genes make all the difference, a genetic test for coronavirus susceptibility could be simple to make, cheap and accurate.

It may be that there are thousands of genes involved. Perhaps a complex mix of genes involved in lung physiology, upper respiratory tract shape, and many other things we have never even thought of. If this is the case, working out exactly what is going on could take decades. But we need answers within weeks or months.

Here we can draw on an unexpected source of inspiration: we can use a method called genomic prediction, which has been used successfully for decades by plant and animal breeders, but is seldom used in medicine. It enables the prediction of complex traits from whole-genome sequences, even when we do not understand what any of the genes are doing.

With this approach, we do not need to spend several years working out what exactly is going on. We can construct a score from a persons whole-genome sequence that predicts their susceptibility. These scores could be obtained at the cost of (we estimate) only a few hundred pounds per person.

We took a genomic prediction approach last year for ash trees, which are dying from a fungal epidemic. By comparing the genomes of healthy versus dying trees, we discovered over 3,000 points in their genomes that contribute to susceptibility. Some of these were in genes that had known functions in host defences, but for many others, we had no idea what they did. Yet we did not need that knowledge to predict the susceptibility of other ash trees with a useful level of accuracy.

Read more: Ash dieback: one of the worst tree disease epidemics could kill 95% of UKs ash trees

We should do similar studies on humans and coronavirus. Of course, there would be more complex issues of privacy and consent than we had to deal with for ash trees. But tens of thousands of human genomes have already been sequenced around the world, so the issues around consent have been well explored. For some coronavirus patients, their genome will already be in a database.

Should we find that we can make accurate predictions, the moral and psychological challenges would be severe. Where should tests be deployed? Will people respond appropriately if they are predicted to be at risk (or not)? How would it affect health insurance? But difficult challenges are faced in every decision that we have to make in our battle against the virus.

Read more: Homemade hand sanitiser recipes that could help protect against coronavirus

Research on the genetic basis of susceptibility to the coronavirus could be done quickly and without diverting resources from research on treatments and vaccines. It might show that predictions are impossible. It might show that accurate predictions can be made. We dont know. But we need to find out. If it worked, it might protect thousands of lives before a vaccine is widely available.

Visit link:
Coronavirus: sequencing the DNA of patients screened for coronavirus might save lives - The Conversation UK